Viatris to Acquire Pacira for $36.50 a Share to Build a Non-Opioid Pain Business

What happened

Viatris announced on Thursday, Oct. 8, that it has agreed to acquire Pacira BioSciences, a maker of non-opioid pain treatments, for $36.50 per share in cash. BioSpace valued the deal at $1.65 billion, while BioPharma Dive described it as a $1.7 billion buyout.

Viatris expects to complete the acquisition by the end of 2026.

Deal and company details

• Price: $36.50 per share in cash.
• Headline value: About $1.65 billion, according to BioSpace.
• Synergies: Viatris expects more than $50 million in cost synergies by the end of 2028.
• Sales force: The deal adds Pacira’s 340-person commercial team.
• Timing: Closing expected by the end of 2026.

Pacira’s main products are Exparel, an injectable form of the local anesthetic bupivacaine used for post-surgical pain and approved in 2011, and Zilretta, an injectable corticosteroid for knee osteoarthritis pain launched in 2017. According to BioSpace, Exparel generated $587 million and Zilretta $121 million across the second half of 2025 and the first half of 2026.

Viatris plans to pair its fast-acting meloxicam, known as FAM and intended for at-home use, with Exparel for hospital inpatients and Zilretta for outpatients. The FDA is scheduled to decide on Viatris’s FAM application by Dec. 27, 2026. Oppenheimer projects FAM could reach peak sales of up to $500 million, BioSpace reported. “We like the fit,” Oppenheimer analysts wrote.

Why it matters for the sector

Non-opioid pain management has become a priority for hospitals, payers and policymakers seeking to reduce opioid exposure after surgery. Drugs that control pain locally or without opioid mechanisms can shorten hospital stays and lower the risk of dependence, and federal policy has encouraged their use in some settings.

For Viatris, which was formed through the combination of Mylan and Pfizer’s Upjohn business and is best known for generic and off-patent branded drugs, the acquisition is part of an effort to build a portfolio of innovative specialty products. Adding a branded franchise with an established sales force gives the company a ready commercial platform for FAM if it is approved.

The transaction also reflects consolidation among mid-sized specialty pharma companies. Single-franchise companies such as Pacira face competitive and pricing pressures on their key products, and a sale to a larger company can offer shareholders a premium while giving the products broader distribution.

The deal’s value depends partly on the FDA decision for FAM. If approved, Viatris would be able to market pain treatments across inpatient, outpatient and home settings through one sales organization, which is the core of its stated rationale.

BioPharma Dive’s deals coverage in the same week also included Shionogi’s IntraBio purchase and GE HealthCare’s agreement to buy Sofie Biosciences, pointing to an active start to the fourth quarter.

The cash consideration means Pacira shareholders receive a fixed price rather than Viatris stock, removing exposure to the combined company’s future performance. For Viatris, a cash deal of this size must be funded from its balance sheet or borrowing, and investors will look for details on financing and leverage in subsequent filings.

What to watch

• Pacira shareholder and regulatory approvals ahead of the expected year-end close.
• The FDA decision on FAM, due by Dec. 27, 2026.
• Integration of Pacira’s commercial team and progress toward the cost synergy target.
• Exparel and Zilretta sales trends through the closing period.

This article is for information only and is not investment advice.

Sources: BioSpace, BioPharma Dive

How a Cash Buyout of a Public Company Usually Proceeds

When a company agrees to be acquired for a fixed cash price per share, the path to closing typically includes several steps:

1. Merger agreement. The boards approve a definitive agreement setting the price, conditions and circumstances under which either side can walk away, often with termination fees.
2. Shareholder approval or tender offer. The buyer either asks target shareholders to vote on the merger or makes a tender offer directly to them to buy their shares.
3. Antitrust review. Premerger notification filings are made, and the transaction can close only after required waiting periods expire.
4. Financing. The buyer arranges cash from its balance sheet, new debt or both.
5. Closing. Shareholders receive the cash price, and the target’s stock stops trading.

Between announcement and closing, the target’s shares usually trade slightly below the offer price. That gap, known as the merger spread, reflects the time value of money and the risk that the deal might not close.

The Products, Explained

Exparel

Exparel is a liposomal formulation of bupivacaine, a long-established local anesthetic. Encapsulating the drug in tiny lipid-based particles is designed to release it gradually at the surgical site, extending pain relief beyond what a standard injection provides.

Zilretta

Zilretta is an extended-release formulation of triamcinolone acetonide, a corticosteroid, delivered in microspheres injected into the knee joint. The extended release is intended to provide longer-lasting relief of osteoarthritis knee pain than a conventional steroid injection.

Fast-acting meloxicam

Meloxicam is a nonsteroidal anti-inflammatory drug, or NSAID, in the same broad class as ibuprofen and naproxen. A fast-acting formulation aims to deliver pain relief more quickly than standard versions.

Understanding Multimodal Pain Management

Modern post-surgical care often uses a “multimodal” approach, combining treatments that work through different mechanisms, such as local anesthetics, anti-inflammatory drugs and acetaminophen. The goal is to control pain effectively while reducing reliance on opioids. Viatris’s stated rationale, linking hospital, outpatient and at-home treatments, draws on that concept by offering options across the different stages of a patient’s recovery. Patients should discuss pain management plans with their surgeons and care teams, since the right approach depends on the procedure and individual health.

Questions Readers Ask

What are cost synergies?

Savings the buyer expects from combining operations, such as eliminating duplicate corporate functions or consolidating systems. They are projections and may not be fully realized.

Why do headline deal values differ between outlets?

Calculations can vary depending on whether they include equity only, assumed debt, cash on hand or other items, as well as share counts used.

What happens to Pacira shares after closing?

In a cash acquisition, shareholders receive the agreed price per share and the stock is typically delisted. Readers should consult a financial professional about their own situation.